The Abramson Cancer Center (ACC) Administration provides centralized coordination of resources and services required to facilitate the ACC's scientific mission to reduce the burden of cancer. Coordinated activities include: support for scientific strategic planning and evaluation, coordination of research program activities, support and oversight of shared facilities, implementation of ACC policies including space and membership, financial management and monitoring, coordination of the ACC pilot projects program, support for education and outreach activities, management of member information databases, and monitoring and reporting for these activities. The ACC Administration is comprised of a cohesive group of highly experienced staff with the demonstrated expertise needed to support the growing research needs of the membership. These key administrative staff members have clearly defined roles and responsibilities, ensuring that the administrative needs of the ACC and its constituents are addressed in an effective and efficient manner. ACC Administration provides vital support to the ACC Director, Senior Leadership, Program Leaders, Advisory Groups, ACC Shared Resources, and ACC members. During the current project period, the ACC administration has played an increasingly important role within the School of Medicine and the Health System, as the volume of clinical care and research has grown with the expansion of both the Adult and Children's Hospitals, the opening of the new outpatient facility within the Perelman Center for Advanced Medicine, and the opening of the Roberts Proton Therapy facility. New activities have included the selection and management of a new clinical trials management system, implementation of a tumor registry, and oversight of the ACC's information technology (IT) infrastructure. The responsibilities of the ACC administration have grown in parallel with the needs of an increasingly active membership and expanding research base, as well as the added responsibilities of managing a greater portion of the ACC's clinical and clinical research activities. It is anticipated that these responsibilities will continue to grow during the next project period. This CCSG budget represents 19% of the total ACC Administration budget and represents less than 10% of the total CCSG budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-39
Application #
8823493
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$572,908
Indirect Cost
$85,972
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5

Showing the most recent 10 out of 1047 publications